AASK NIH Cohort Study

高血压肾病通常进展。AASK（African American） 肾脏疾病和高血压的研究）队列研究是为了前瞻性地确定肾脏疾病的病程， 非裔美国人高血压肾病患者的肾功能和肾脏疾病进展的危险因素 接受推荐的抗高血压治疗的患者。第二个目标是确定 心血管疾病的发生，并评估其危险因素。 AASK队列研究是一项前瞻性、观察性研究，是AASK试验的扩展。的 AASK试验检测了3种药物（雷米普利、美托洛尔）作为初始抗高血压治疗的效果 和2级血压控制。在1，094名试验参与者中，约有650至 700名未达到终末期肾病（ESRD）的个体可能会入组队列研究。 要研究的风险因素包括环境、遗传、生理和社会经济变量。的 主要肾脏结局是一种复合临床结局，定义为血清肌酐、ESRD或 死亡高血压的药物治疗，从血管紧张素转换酶抑制剂开始 ，并提供给所有参与者。以这种方式，该研究直接控制了两个主要决定因素 肾脏疾病进展（治疗高血压和使用肾脏保护、抗高血压 药物）。队列研究的最短随访时间为5年（共9 - 12年， 包括AASK试验期间）。 最终，来自AASK队列研究的数据应该增强我们对风险因素的理解， 决定肾脏疾病进展的过程。这样的结果最终可能会导致新的 延缓或预防ESRD的策略__

Hypertensive kidney disease commonly progresses. The primary objective of the AASK (African American Study of Kidney Disease and Hypertension) Cohort Study is to determine prospectively the course of kidney function and risk factors for kidney disease progression in African-Americans with hypertensive kidney disease who receive recommended antihypertensive therapy. A secondary objective is to determine the occurrence of cardiovascular disease and assess its risk factors. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK trial. The AASK trial tested the effects of 3 medications used as initial antihypertensive therapy (ramipril, metoprolol and amlodipine) and 2 levels of blood pressure control. Of the 1,094 trial participants, approximately 650 to 700 individuals who have not reached end stage renal disease (ESRD) will likely enroll in the Cohort Study. Risk factors to be studied include environmental, genetic, physiologic, and socio-economic variables. The primary renal outcome is a composite clinical outcome defined by doubling of serum creatinine, ESRD, or death. Medication treatment for hypertension, beginning with the angiotensin converting enzyme inhibitor ramipril, is offered to all participants. In this fashion, the study directly controls two of the major determinants of kidney disease progression (treatment of hypertension and use of reno-protective, antihypertensive medication). The minimum duration of follow-up in the Cohort Study is 5 years (total of 9 to 12 years, including the period of the AASK trial). Ultimately, data from the AASK Cohort Study Should enhance our understanding of the risk factors and processes that determine the progression of kidney disease. Such results might eventually lead to new strategies that delay or prevent ESRD__